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Background: Management of diabetes without any side effects is still a challenge to the medical system. This leads
to increasing demand for natural products with antidiabetic activity with fewer side effects. Grewia hirsuta (Tiliaceae)
is a traditional herbal medicinal plant and is reported to possess a variety of pharmacological actions. In the present
research, a compound (4Z, 12Z)-cyclopentadeca-4, 12-dienone isolated from Grewia hirsuta was taken as ligand for
molecular docking studies. Evaluation of hypoglycemic activity through an extensive in silico docking approach
with molecular targets such as aldose reductase, glucokinase, pyruvate dehydrogenase kinase isoform 2, peroxisome
proliferator-activated receptor-gamma, glycogen synthase kinase-3, 11β-Hydroxysteroid dehydrogenase, and glutamine:
fructose-6-phosphate amidotransferase were performed.
Methods: Isolation of the (4Z, 12Z)-cyclopentadeca-4,12-dienone from the methanol extract of the leaves of Grewia
hirsuta was performed by the column chromatography to yield different fractions. These fractions were then subjected
to purification and the structure was elucidated and confirmed by spectroscopic methods including UV, FTIR, 1H, 13C
NMR and the accurate mass determination was carried out using the Q-TOF mass spectrometer. In-vivo experimentation
was performed with evaluation of α-glucosidase, α-amylase and MTT assay that had been reported by the author in the
earlier paper. Molecular docking study was performed with GLIDE docking software.
Results: The docking studies of the ligand (4Z, 12Z)-cyclopentadeca-4, 12-dienone with seven different target
proteins showed that this is a good inhibitor, which docks well with various targets related to diabetes mellitus. Hence
(4Z, 12Z)-cyclopentadeca-4,12-dienone can be considered for developing into a potent anti-diabetic drug.
Conclusion: The results of the current study have revealed that the leaves of the selected plant Grewia hirsuta contains
a potential inhibitor for diabetes (4Z, 12Z)-cyclopentadeca-4,12-dienone. Thus enabling a possibility of this plant extract
as a new alternative to existing diabetic approaches.
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Diabetes mellitus is a metabolic disorder characterized
by a loss of glucose homeostasis with disturbances of
carbohydrate, fat and protein metabolism resulting from
defects in insulin secretion, insulin action, or both [1].
The word “diabetes” is derived from the Greek word
“Diab” (meaning to pass through, referring g to the cycle
of heavy thirst and frequent urination); “mellitus” is the* Correspondence: shobana.s@ktr.srmuniv.ac.in
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unless otherwise stated.Latin word for “sweetened with honey” (refers to the
presence of sugar in the urine) [2]. According to ancient
Hindu physicians, “Madhumeha” is a disease, in which a
patient passes sweet urine and exhibits sweetness all
over the body,such as in sweat, mucus, breath, and blood
[3]. It was recommended that the low carbohydrate diet
and almost total withdrawal of animal fats should be
taken by the patients suffering from Madhumeha, whereas
obese adults should live on low calorie diet. Diabetes has
been known in India for centuries as ‘a disease of rich man’
but is now spread among all masses [4]. It is becoming the
third “killer” of the health of mankind a long with cancer,ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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being a natural reservoir of many medicinal value
added components help to overcome many chronic
disorders. The use of allopathic drugs had caused severe
side effects and not found to be cost effective. Hence
herbal medicines are considered to be an excellent remedy
for diseases like cancer, diabetes, liver diseases and
arthritis. The bioactive compounds of medicinal plants
are used as anti diabetic, chemotherapeutic, anti inflam-
matory, anti arthritic agents where no satisfactory cure is
present in modern medicines [6]. Herbal drugs are
prescribed due to their good effectiveness, fewer side
effects in clinical experience and relatively low costs
[7]. There are various types of phytoconstituents present
in the plants to treat this metabolic disorder. The plant of
interest Grewia hirsuta (family: Tilaceae) has many
phytochemical constituents such as Aldehyde, Alcoholic
compound, α-Curcumene, Sesquiterpene, Sesquiterpene
alcohol, Undecanoic acid,Tetradecanoic acid Myristic
acid,Sesquiterpene oxide, n-hexadecanoic acid, Palmitic
acid,Linoleic acid,Oleic Acid, Gingerol and Alkane which
has been isolated from the leaf extract for the study of
cardio protective potential [8]. The plant extract is used as
anti-fertility [9], anti-ulcer and aphrodisiac agent [10].
Dried roots of this plant are administered along with
few other ingredients to cure colic and rheumatic
ailments in cattle [11]. For the first time, a compound
(4Z, 12Z)-cyclopentadeca-4, 12-dienone with potent
anti diabetic efficacy had been isolated from this plant
that has been reported by the author in the earlier paper
[12]. Molecular docking is an important computational
tool to predict the plausible interactions between the drug
and protein in a non-covalent fashion. Extensive in silico
docking procedures have been carried out to examine
whether the compound is a good ligand with diabetic
targets such as Aldose reductase, Peroxisome proliferator-
activated receptor-gamma, Glycogen synthase kinase-3,
Pyruvate dehydrogenase kinase isoforms 2, Glucokinase,
11β-Hydroxysteroid dehydrogenase, Glutamine:fructose-
6-phosphate amidotransferase.
Aldose reductase (ALR2; EC 1.1.1.21) (PDB ID 3G5E) is
the rate-limiting enzyme in the Polyol pathway. It reduces
excess D-glucose into D-sorbitol with the help of
NADPH as a cofactor (El-Kabbani et al., 2004) [13]. It plays
important role in diabetic microvascular complications
(Kaul and Ramarao, 2001) [13,14]. Peroxisome proliferator-
activated receptor-gamma (PDB ID 3DZY) key transcrip-
tional factor plays a pivotal role in regulating adipogenesis,
insulin sensitivity and glucose homeostasis [15,16].
Glycogen synthase kinase-3 (PDB ID 3F7Z) is a unique
multifunctional serine/threonine kinase and it was inacti-
vated by phosphorylation. In response to insulin binding,
PKB/AKT phosphorylates GSK-3 on serine 9, which pre-
vents the enzyme from phosphorylating glycogen synthase[17]. Unphosphorylated glycogen synthase is active and able
to synthesize glycogen. Thus it plays a key role in the
transduction of regulatory and proliferative signals
arising out at the cell membrane in the insulin signalling
pathway, leading to potential modulation of blood glucose
levels [17]. Pyruvate dehydrogenase kinase isoforms
(PDKs 1 - 4) (PDB ID 4MP2) negatively regulate activity of
the mitochondrial pyruvate dehydrogenase complex (PDC)
by reversible phosphorylation. PDK isoforms are up-
regulated in obesity, diabetes, heart failure and cancer and
are potential therapeutic targets for these important
human diseases [18]. Glucokinase (hexokinase IV) has a
major role in the control of blood glucose homeostasis
because it is the predominant hexokinase expressed in the
liver, has a very high control strength on hepatic glucose
disposal, and is the glucose sensor for insulin secretion in
pancreatic β-cells. Glucokinase (PDB ID-4IXC) is currently
considered a strong candidate target for antihyperglycemic
drugs for type 2 diabetes [19]. 11β-Hydroxysteroid
dehydrogenase (11β-HSD) (PDB ID 4K1L) enzymes catalyze
the conversion of biologically inactive 11-ketosteroids
into their active 11β-hydroxy derivatives and vice
versa. Inhibition of 11β-HSD1 has considerable therapeutic
potential for glucocorticoid-associated diseases including
obesity, diabetes, wound healing, and muscle atrophy
[20,21]. Glutamine:fructose-6-phosphate amidotransferase
(GFAT) (PDB ID 2ZJ4) is a rate-limiting enzyme in the
hexoamine biosynthetic pathway and plays an important
role in type 2 diabetes [22]. The enhanced activity of
human GFAT has been implicated in insulin resistance in
cellular and animal models. Thus, human GFAT is recog-
nized as an interesting potential target for type 2 diabetes
complications in medicinal chemistry [23]. To the best of
our knowledge, this is the first report on docking studies of
the compound (4Z, 12Z)-cyclopentadeca-4, 12-dienone
isolated from Grewia hirsuta for antidiabetic activity.
Methods
The fresh leaves of Grewia hirsuta plants were collected
from Malachery forest, Gingee, Thiruvannamalai District,
TamilNadu. The plant specimen was authenticated and
voucher specimen (SRMU/BI/5) was deposited in the
Herbarium at Proteomics lab, SRM University. The extrac-
tion was done from shade, dried and coarsely powdered
leaves of the plant Grewia hirsuta (about 50gms) using
methanol in a Soxhlet apparatus for 16 h. After column
fractionation (E-Merck, Darmstadt, Germany and dimen-
sion of column was 450 x 30 mm) the compound (4Z,
12Z)-cyclopentadeca-4,12-dien-1-one with hypoglycemic
activity was separated and was concentrated by a speed-vac
under low pressure with evaporating temperature of 40°C.
TLC was performed on a pre-coated silica gel TLC plates
grade F254 (E-Merck, Darmstadt, Germany) to determine
the number of compounds present in the given sample.
Figure 1 Compounds separation by Thin layer chromatography.
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firmed by spectroscopic methods including UV, FTIR
(direct sampling method using TENSOR II FT-IR Spec-
trometer, Bruker, and Mumbai, India). 1H, 13C NMR
(300 MHz) studies and the accurate mass determination
were also carried out using the Q-TOF mass spectrometer
available with electron spray ionization (ESI) (Micromass
UK Ltd). All the above results were reported in the earlier
paper by the author [12]. The elemental analysis was also
carried out using Flash EA, Thermo Finnigan (Italy).
Molecular docking analysis
The structures of the target receptor binding sites of hu-
man aldose reductase (PDB ID-3G5E), glucokinase,
(PDB ID-4IXC), pyruvate dehydrogenase kinase (PDB
ID-4MP2), peroxisome proliferator-activated receptor-
gamma (PDB ID-3DZY), glycogen synthase kinase-3
(PDB ID-3F7Z),11β-Hydroxysteroid dehydrogenase
(PDB ID-4K1L), glutamine:fructose-6-phosphate (PDB
ID-2ZJ4) were retrieved from the RCSB Protein Data
Bank (http://www.rcsb.org/pdb/home/home.do). The dock-
ing calculations were performed using the Schrödinger
software suite with default settings if not indicated
otherwise [24]. The proteins were prepared by using
the Protein Preparation Wizard, pre-processed and
heterostate for co-crystallized ligand was generated
using Epik; protonation state and optimization of H
bonding of the protein side chains were assigned using
Protassign, energy minimization (impref minimization)
was carried out using default constraint of 0.3 Å RMSD
and OPLS 2005 force field. Receptor grid has been
prepared with default parameters and without any
constrains. The ligand was prepared by using Ligprep
utility of Schrodinger Suite with default parameters,
the ligand energy minimized by using OPLS 2005
(Macromodel multiple minimization) and water as solvent
[24]. Ligand docking was performed using OPLS force
field. In order to predict the binding affinity and pre
eminent docked structures, the combined ligand docking
and energy-grid scores were ranked by using E model and
Glide scores. Docking was performed using the Extra
Precision (XP) feature of GLIDE 5.0 module implemented
in the Schrodinger LLC [24]. Visualization and analysis of
protein–ligand complexes was performed using PyMOL
ver. 0.99 software (De Lano Scientific LLC, CA, USA)
[25]. The PDB Sum (http://www.ebi.ac.uk/pdbsum/) ser-
ver was used to determine the active sites of the receptors
and their interactions with the compound.
ADME/T property analysis
The QikProp module of Schrodinger is a quick, accurate,
easy-to-use absorption, distribution, metabolism, and
excretion (ADME) prediction program design to produce
certain descriptors related to ADME. It predicts bothphysicochemical significant descriptors and pharmacoki-
netically relevant properties. ADME properties determine
drug-like activity of ligand molecules based on Lipinski’s
rule of five. ADME/T properties of the compound (4Z,
12Z-Cyclopentadeca-4, 12-dien-1-one was analysed using
Qikprop 3.2 module [26].
Result and discussion
Under the influence of UV, four distinct compounds with
Rf values 0.876, 0.765, 0.634 and 0.500 were recognized.
When treated with iodine compounds with Rf values 0.765,
0.634 and 0.500 were seen. (4Z, 12Z)-cyclopentadeca-4, 12-
dienone was an orange yellowish oily colored compound
(yield: 650 mg) with the Rf value of 0.876 (9:1, chloroform:
methanol) on TLC was observed with m.pt 68-69°C
(Figure 1). Among the compounds, (4Z, 12Z)-cyclopenta-
deca-4, 12-dienone (Rf =0.876) gave good result of 52.3%
α-amylase inhibitory activity and the other compounds
gave only poor results on inhibitory effect [12]. The
Q-TOF spectrum of (4Z, 12Z)-cyclopentadeca-4, 12-
dienone showed a molecular ion peak at m/z 220
(100%,) (Figure 2) indicating the molecular weight
with molecular formula is C15H24O (Figure 3). UV
(methanol): λmax = 221 nm (double bonds presence),
at 528 nm (coloured compound) (Figure 4). FTIR studies:
υmax at 1711 cm
−1 (presence of carbonyl group), 1641 cm−1
(–C=C), 2924–2853 cm −1 (–CH 2) [12]. The
1H NMR
(CDCl3, 300 MHz) δ: 5.02-5.13 (m, olefinic protons),
0.86-2.10 (m, CH2 protons) The
13CNMR (CDCl3,
300 MHz) δ: 22.70- 39.77 ppm [presence of carbons in the
aliphatic regions (-CH2)],173.77 (carbonyl carbon), 124.45
and 134.90 (olefinic carbons) [12]. The elemental analysis
report revealed the presence of C (84.76%), H (8.98%) and
O (6.26%) in the compound and absence of N.
Figure 2 Q-TOF mass spectrum of (4Z, 12Z)- Cyclopentadeca-4, 12-dienone.
Natarajan et al. BMC Complementary and Alternative Medicine  (2015) 15:73 Page 4 of 8In order to investigate the binding capacity of bio-
active compound in Grewia hirsuta on proteins related
to diabetes in humans, we docked the compound to the
target proteins. Results showed that the dock score
ranged from -5.21 to -7.85 (kcal/mol) (Table 1). High
binding affinity of the ligand to the receptor was
explained clearly by interaction analysis (Figure 5).
Glutamine: fructose-6-phosphate amidotransferase
(GFAT) is the key enzyme in the hexoamine biosynthetic
pathway and plays an important role in type 2 diabetes
[22]. In our study, docking of novel compound with 2ZJ4
showed binding interaction of Keto group of the novel
compound established the hydrogen bond with SER 473
which is the major interaction of the ligand with 2ZJ4.
THR 425, SER 373, SER 422, SER 420, GLN 421 and SER
376 residues which are presented in the active site form
strong polar interactions with the compound. ALA
472, LEU 556, GLY 374, VAL 471, VAL 677, CYS 373
form strong hydrophobic interactions. LYS 675, LYSFigure 3 Molecular structure of (4Z, 12Z)- Cyclopentadeca-4,
12-dienone.557 positively charged amino acids and negatively
charged GLU 560 present in active site interacts with
the compound. Similar interactions were observed in
substrate 2-Deoxy 2- amino glucitol 6-phosphate inter-
action with GFAT [22].
The Molecular Docking analysis of the novel com-
pound and the receptor 3DZY (intact PPAR gamma -
RXR alpha Nuclear Receptor Complex on DNA bound
with Rosiglitazone, 9-cis Retinoic Acid and NCOA2
Peptide) showed that ILE-268,CYS-432,PHE-439,LEU-694,
VAL-342,VAL-265,ILE-345,VAL-349,PHE-346,PHE-313,
ILE-310,ALA-272 residues form strong hydrophobic
interactions and HIS 435 forms polar contact with the
compound. Similar amino acid interactions are seen
in potential retinoid X receptor targretin agonists for
treating Alzheimer’s disease from traditional Chinese
medicine [23].
Glucocorticoids (GCs) are potent functional antagonists
of insulin action, and promote gluconeogenesis in the
liver, potentially leading to raised blood glucose concen-
trations in diabetes. At the tissue level the access of active
GCs to its receptors is governed by 11β-HSD1 [20]. The
docking studies of 11β-HSD1with the compound makes
reveals the best dock score of -7.85 kcal/mol and interact
with hydrophobic residues such as ALA 226, Val 227, VAL
180, LEU 126, TYR 177, PRO 178, VAL 231, MET233
LEU 215, LEU 171, TYR 183 and ALA 223.GLY 216 and
polar residue SER 170 are also involved in the interaction
with the compound. These interactions clearly suggest
that the compound fits very well into the binding pocket
of 11β-HSD1. This conclusion is strongly supported
by previous study on 1, 1-Dioxo-5, 6-dihydro-[1,2,4]
oxathiazines, a novel class of 11ß-HSD1 inhibitors for
the treatment of diabetes [21]. PDK plays a crucial role in
glucose utilization and lipid metabolism through pyruvate
dehydrogenase complex. In diabetes, PDK2 activity is
markedly upregulated and PDK2 has been an emerging
therapeutic target for type 2 diabetes as well as a candidate
Figure 4 UV-Vis spectrum of (4Z, 12Z)- Cyclopentadeca-4, 12-dienone.
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(Crystal structure of pyruvate dehydrogenase kinase
isoform 2 in complex with inhibitor PA1) with the novel
compound revealed that ARG 258 forms the strong hydro-
gen bond interaction with C =O of the novel compound.
LEU 330,LEU 346,LEU 303, VAL 295,ALA 256, ALA 259
residues form hydrophobic interactions [27]. Polar residues
ASN 255, THR 354and SER 263 present in the binding site
interact with the compound. GLY at position 292 and 293
involved in interaction with the compound. Negatively
charged ASP 290 and GLU 262 present in the binding
pocket were found to be interacting with the compound.
Our results coincide with the active site interaction of
(5-Bromo-2, 4-Dihydroxyphenyl)(1,3-Dihydro-2 h-Isoindol-
2-Yl) methanone with ATP binding pocket [18,28].
Since aldose reductase inhibitors can play a significant
role in preventing diabetic complications [29,30]. In the
present study docking of 3G5E and the novel compound
revealed PHE 122, PRO 218,TRP 219,LEU 300,CYS 298,
TRP 111,TRP 48,TRP 79,VAL 47,TYR 48 residues form
strong hydrophobic interactions. Polar residues GLN
49and HIS 110 present in active site also interact with
the novel compound. The novel compound interacts in
the similar manner like zenarestat inhibitor fits neatly in the
hydrophobic active site and induces unique and dramatic
conformational changes [31].Table 1 Inhibitory activity of (4Z,12Z)-cyclopentadeca-4,












2 3DZY −7.57 −43.74 −30.62
3 3F7Z −6.01 −39.45 −28.72
4 4MP2 −5.21 −32.80 −26.26
5 4IXC −6.18 −34.06 −22.81
6 4K1L −7.85 −43.79 −26.06
7 2ZJ4 −5.57 −43.23 −32.54Glucokinase (GK) is expressed in various organs and
plays a key role in hepatic glucose metabolism and
pancreatic insulin secretion. GK could indeed serve as
pacemaker of glycolysis and could be an attractive
target for type 2 diabetes (T2D) [17]. In the present
study the novel compound reveals strong hydrophobic
interaction with residues VAL 62, CYS 252,ILE 211,
VAL 452,VAL 455,PRO 66,THR 214,MET 235 and MET
210 . Positively charged ARG 63, negatively charged
GLU 67 and GLU 227 interact with novel compound
respectively. Polar residues present in the binding
pocket SER 64, THR 65 interacts with the novel com-
pound. Similar interactions were observed in (2 s)-2-{[1-(3-
Chloropyridin-2-Yl)-1 h-Pyrazolo [3,4-D]pyrimidin-4-Yl]
oxy}-N-(5-Methylpyridin-2-Yl)-3-(Propan-2-Yloxy) propa-
namide inhibitor with 4IXC [32]. Our docking results. The
binding interactions and involvement of specific amino
acid could lead to design of novel glucokinase activator
with higher selectivity and least side effects for the
treatment of type 2 diabetes and related disorders.
GSK-3 plays a key role in the regulation of beta cell
mass and is a target for beta cell regenerative therapies.
Docking study on Glycogen Synthase Kinase 3beta (PDB
Code 3F7Z) and the novel compound revealed that the
oxygen atom of the novel compound reacts with LYS-85
and forms hydrogen bond. Strong hydrophobic interaction
was observed around the cyclopentane ring such as
near the VAL-110,LEU-132,ALA-83,LEU-188,VAL-135,
CYS-199 and PHE-67, polar interactions also occurs
with amino acids such as Thr 138 and Asn-186 [33].
ADMET predictions
The drug-like activity of the ligand molecule is charac-
terized using ADME properties. ADME prediction can
be used to focus lead optimization efforts to enhance the
desired properties of a given compound. The expected
ADME property of the tested compound was evaluated
with QikProp module of Schrodinger (Table 2). The








Figure 5 Molecular docking of (4Z, 12Z)- Cyclopentadeca-4, 12-dien-1-one with the active site residues of selected target proteins.
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Table 2 Qikprop admet property results
Entry name Human oral absorptiona QPlogPo/wb CNSc mol MWd donorHBe accptHBf Rule of fiveg
(4Z, 12Z)- Cyclopentadeca-4, 12-dienone 80 4.393 −2 220 2 4 0
a% Human oral absorption: <25% is poor absorption. bQPlogPo/w: Partition coefficient; recommended range -2.0 - 6.5. cCNS: Predictive Central Nervous Activity -2
(inactive) to +2 (active). dM.wt.: Molecular weight of the molecule < 500 is preferred. edonor HB: Estimated number of hydrogen bonds that would be donated by the
solute to water molecules in an aqueous solution, recommended range 0.0 - 6.0 faccpt HB: Estimated number of hydrogen bonds that would be accepted by the solute
from water molecules in an aqueous solution, recommended range 2 - 20. gRule of five: Number of violations of Lipinski’s rule of five; recommended range 0 - 4.
Natarajan et al. BMC Complementary and Alternative Medicine  (2015) 15:73 Page 7 of 8cell permeation, and bioavailability. Almost all the pre-
dicted properties of the tested compound was in the
range as predicted by QikProp for 95% of known oral
drugs and also satisfy the Lipinski’s rule of five to be
considered as drug like potential.
Conclusion
Docking studies of the (4Z, 12Z)- Cyclopentadeca-4,
12-dienone with seven different target proteins showed
that this is a promising candidate which docks well with
various targets related to diabetes mellitus. ADME
properties can be taken as best hit molecule and can
be considered for further studies like QSAR. Thus
(4Z, 12Z) - Cyclopentadeca-4, 12-dienone can be con-
sidered for developing into a potent antidiabetic drug.
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